Oral Cancer Clinical Trial
Official title:
Effects of Mouth-opening Training With Follow-up Telephone Calls on the Maximum Interincisal Opening and Mandibular Function of Postoperative Oral Cancer Patients: A Randomized Clinical Trial
NCT number | NCT03875118 |
Other study ID # | 20110818B |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 18, 2012 |
Est. completion date | March 31, 2014 |
Verified date | April 2021 |
Source | National Taipei University of Nursing and Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PURPOSE:The purpose of the study was to investigate the effect of mouth-opening training with follow-up telephone calls for reducing postoperative trismus in patients with oral cancer. METHODS:The study is a randomized clinical trial using repeated measures. Sixty-eight patients admitted at a general hospital in Taiwan for oral cancer surgery were recruited and randomly assigned to either the intervention or control group. All subjects were instructed to practice mouth-opening exercises three times a day every day for three months. Subjects in the intervention group received additional 6 follow-up phone calls to enhance mouth-opening exercise adherence. Data on maximum interincisal opening and mandibular function impairment were collected before surgery, at one-month, and three-months after discharge, using the TheraBite Range-of-Motion scale and Mandibular Function Impairment Questionnaire.
Status | Completed |
Enrollment | 68 |
Est. completion date | March 31, 2014 |
Est. primary completion date | March 31, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. aged 18 years or older 2. diagnosed with oral cancer 3. scheduled for a primary curative oral cancer surgery 4. able to communicate in Mandarin or Taiwanese 5. obtained medical clearance from the patient's attending physician to participate in the study Exclusion Criteria: 1. diagnosed with lip or tongue cancers which were less relevant to trismus 2. had central incisors extracted during the surgery |
Country | Name | City | State |
---|---|---|---|
Taiwan | Yuan's General Hospital | Kaohsiung |
Lead Sponsor | Collaborator |
---|---|
National Taipei University of Nursing and Health Sciences | Yuan's General Hospital |
Taiwan,
Agarwal P, Shiva Kumar HR, Rai KK. Trismus in oral cancer patients undergoing surgery and radiotherapy. J Oral Biol Craniofac Res. 2016 Nov;6(Suppl 1):S9-S13. Epub 2016 Oct 22. — View Citation
Chen M, Li P, Lin F. Influence of structured telephone follow-up on patient compliance with rehabilitation after total knee arthroplasty. Patient Prefer Adherence. 2016 Mar 3;10:257-64. doi: 10.2147/PPA.S102156. eCollection 2016. — View Citation
Kamstra JI, van Leeuwen M, Roodenburg JLN, Dijkstra PU. Exercise therapy for trismus secondary to head and neck cancer: A systematic review. Head Neck. 2017 Nov;39(11):2352-2362. doi: 10.1002/hed.24859. Epub 2017 Jul 14. — View Citation
Wetzels JW, Merkx MA, de Haan AF, Koole R, Speksnijder CM. Maximum mouth opening and trismus in 143 patients treated for oral cancer: a 1-year prospective study. Head Neck. 2014 Dec;36(12):1754-62. doi: 10.1002/hed.23534. Epub 2014 Jan 30. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | TheraBite Range-of-Motion Scale | The TheraBite® Range-of-Motion Scale was used to measure the maximum incisal opening (MIO), which is the maximal vertical distance between the edges of the incisors of the maxilla and the mandible. The TheraBite® Range-of-Motion Scale is a disposable paper measuring scale specially designed to measure a subject's mouth and jaw opening. The subject sits in an upright position with his mouth open wide. For measuring the vertical opening, the scale has a possible range of 5 to 70 mm, with the notch is placed on the lower incisor midline. The usual range of MIO is between 40 and 55 mm. Subjects with MIO <35 mm are considered to have trismus. | Change from Baseline to 3 months | |
Secondary | Mandibular Function Impairment Questionnaire (MFIQ) | The MFIQ (Mandibular Function Impairment Questionnaire) was used to measure the extent of patients' mandibular function impairment. The questionnaire consists of 17 items, each of which targets a specific oral function impairment; including difficulties in social activity, speech, taking a large bite, chewing hard food, chewing soft food, work and/or daily activities, drinking, laughing, chewing resistant food, yawning, kissing, and eating different types of food. The subjects were asked to indicate how much difficulty they had with each activity or with eating each type of food using a 5-point Likert scale (0 = no difficulty, 4 = very difficult or impossible without help). The total score of the 17 items divided by 68 provides the scale score, with a possible range of 0 to 1. A higher score indicates greater severity of the mandibular function impairment. A score = 0.3, between 0.3 and 0.6, and >0.6 indicates mild, moderate, and severe mandibular function impairment, respectively. | Change from Baseline to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
Completed |
NCT00158678 -
IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC
|
Phase 3 | |
Completed |
NCT00933387 -
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 2 | |
Enrolling by invitation |
NCT05030597 -
Exploring the Application Value of PET Molecular Imaging Targeting FAP in Oral Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Recruiting |
NCT03684707 -
Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions
|
Phase 4 | |
Recruiting |
NCT06130332 -
Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)
|
Phase 2 | |
Recruiting |
NCT04372914 -
Prevention of Oral DNA Damage by Black Raspberries
|
N/A | |
Active, not recruiting |
NCT03529422 -
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
|
Phase 2 | |
Recruiting |
NCT03686020 -
Sensitivity and Specificity of Serum and Salivary CYFRA21-1 in the Detection of Malignant Transformation in Oral Potentially Malignant Mucosal Lesions (Diagnostic Accuracy Study)
|
||
Not yet recruiting |
NCT06060288 -
Diagnostic Accuracy of Mobile Phone Imaging Compared to Conventional Clinical Examination for Oral Cancer Screening
|
||
Withdrawn |
NCT00951470 -
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
|
N/A | |
Completed |
NCT00964977 -
Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis.
|
Phase 3 | |
Completed |
NCT01418118 -
Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery
|
Phase 4 | |
Active, not recruiting |
NCT00232960 -
Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC
|
N/A | |
Recruiting |
NCT05429099 -
Mandibular Reconstruction Preplanning (ViPMR)
|
Phase 2/Phase 3 | |
Completed |
NCT04614896 -
Use of Ultrasound for Measuring Size of Oral Tongue Cancers
|
N/A | |
Recruiting |
NCT03685409 -
Cancer Chemoprevention by Metformin Hydrochloride in Oral Potentially Malignant Lesions
|
Phase 3 | |
Completed |
NCT00402779 -
Erlotinib Prevention of Oral Cancer (EPOC)
|
Phase 3 | |
Recruiting |
NCT05153733 -
Improved Implant for Reconstruction Purposes After Mandibular Resection
|
N/A |